CASI Pharmaceuticals starts OTCQB trading as CASIF
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, reported that its ordinary shares began trading on the OTCQB market under the ticker CASIF on April 14, 2026.
The information in this report is incorporated by reference into the company’s existing shelf registration statements on Form F-3, allowing it to be used in connection with those offerings. The report also reiterates standard forward-looking statement cautions under the U.S. Private Securities Litigation Reform Act of 1995.
Key Figures
OTCQB trading start date: April 14, 2026
Commission File Number: 001-41666
Registration Statements referenced: Form F-3 File Nos. 333-283998, 333-281621
+1 more
4 metrics
OTCQB trading start date
April 14, 2026
Date CASI ordinary shares began OTCQB quotation as CASIF
Commission File Number
001-41666
Exchange Act registration reference in Form 6-K
Registration Statements referenced
Form F-3 File Nos. 333-283998, 333-281621
Form 6-K information incorporated by reference
Form type
Form 6-K
Report of foreign private issuer for April 2026
Key Terms
OTCQB, foreign private issuer, Registration Statements on Form F-3, anti-CD38 monoclonal antibody, +2 more
6 terms
OTCQB financial
"the Company’s ordinary shares began to be quoted for trading on the OTCQB under the ticker CASIF"
OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Registration Statements on Form F-3 regulatory
"incorporated by reference into the Company's Registration Statements on Form F-3"
anti-CD38 monoclonal antibody medical
"developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection"
Private Securities Litigation Reform Act of 1995 regulatory
"made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"
forward-looking statements regulatory
"This announcement contains forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CASI (CASI) announce in its April 2026 Form 6-K?
CASI Pharmaceuticals announced that its ordinary shares began trading on the OTCQB market under ticker CASIF on April 14, 2026. The report also incorporates this information by reference into its existing Form F-3 registration statements and includes standard forward-looking statement cautions.
What type of company is CASI Pharmaceuticals (CASI)?
CASI Pharmaceuticals is described as a clinical-stage biopharmaceutical company. It is developing CID-103, an anti-CD38 monoclonal antibody intended for patients with organ transplant rejection and autoimmune diseases, according to the business description included in its April 2026 Form 6-K report.
What is CID-103 in CASI Pharmaceuticals’ pipeline?
CID-103 is an anti-CD38 monoclonal antibody being developed by CASI Pharmaceuticals. The company states it is targeting patients with organ transplant rejection and autoimmune diseases, highlighting its focus on immune-related conditions in its clinical-stage biopharmaceutical development activities.
How is this 6-K incorporated into CASI Pharmaceuticals’ SEC registrations?
The company states that the information in this Form 6-K is incorporated by reference into its Form F-3 registration statements, File Nos. 333-283998 and 333-281621. This allows the disclosed OTCQB trading information to become part of those existing shelf registration documents for regulatory and offering purposes.
What forward-looking statement warnings does CASI include in this filing?
CASI notes this announcement contains forward-looking statements made under the safe harbor of the U.S. Private Securities Litigation Reform Act of 1995. It explains such statements involve risks and uncertainties, and refers readers to its SEC filings for further risk information, cautioning against undue reliance on these statements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates